Drug intelligence / Profile preview

pembrolizumab + MRG003

Development stage: Unknown
Lead developer: Lepu Biopharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination therapy consists of pembrolizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, and MRG003 (becotatug vedotin), an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR). Pembrolizumab, developed by Merck, acts as a checkpoint inhibitor to enhance the immune system's anti-tumor response. MRG003, developed by Lepu Biopharma, consists of an anti-EGFR humanized IgG1 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a valine-citrulline linker. This combination is being investigated as a neoadjuvant and adjuvant treatment in a Phase II trial conducted by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology for patients with Epstein-Barr virus (EBV)-associated locoregionally advanced nasopharyngeal carcinoma.

Brand names: Keytruda
Other names: pembrolizumab + becotatug vedotin

Targets

PDCD1 (Programmed cell death protein 1 receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on pembrolizumab + MRG003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + MRG003.

Explore the full profile